Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer

MLA

Alex Makalinao, et al. “Phase II Study of PKC-α Antisense Oligonucleotide Aprinocarsen in Combination with Gemcitabine and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer.” Lung Cancer, vol. 52, May 2006, pp. 173–80. EBSCOhost, https://doi.org/10.1016/j.lungcan.2005.12.012.

APA

Alex Makalinao, David Irwin, Jacob D. Bitran, Patrick Peterson, Martin J. Edelman, Rogerio Lilenbaum, Charles M. Rudin, William J. John, & Paul S. Ritch. (2006). Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer, 52, 173–180. https://doi.org/10.1016/j.lungcan.2005.12.012

Chicago

Alex Makalinao, David Irwin, Jacob D. Bitran, Patrick Peterson, Martin J. Edelman, Rogerio Lilenbaum, Charles M. Rudin, William J. John, and Paul S. Ritch. 2006. “Phase II Study of PKC-α Antisense Oligonucleotide Aprinocarsen in Combination with Gemcitabine and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer.” Lung Cancer 52 (May): 173–80. doi:10.1016/j.lungcan.2005.12.012.